DK1490100T3 - Kombinerede DNA/proteinvaccinepræparater - Google Patents

Kombinerede DNA/proteinvaccinepræparater

Info

Publication number
DK1490100T3
DK1490100T3 DK03720397.3T DK03720397T DK1490100T3 DK 1490100 T3 DK1490100 T3 DK 1490100T3 DK 03720397 T DK03720397 T DK 03720397T DK 1490100 T3 DK1490100 T3 DK 1490100T3
Authority
DK
Denmark
Prior art keywords
dna
combined dna
protein vaccine
vaccine preparations
combined
Prior art date
Application number
DK03720397.3T
Other languages
English (en)
Inventor
Hansjoerg Reimann
Reinhold Alois Schirmbeck
Erik B Lindblad
Original Assignee
Brenntag Biosector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brenntag Biosector As filed Critical Brenntag Biosector As
Application granted granted Critical
Publication of DK1490100T3 publication Critical patent/DK1490100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03720397.3T 2002-03-28 2003-03-28 Kombinerede DNA/proteinvaccinepræparater DK1490100T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02076276 2002-03-28
EP03075383 2003-02-10
PCT/EP2003/003353 WO2003082327A2 (en) 2002-03-28 2003-03-28 Combined dna/protein vaccine compositions

Publications (1)

Publication Number Publication Date
DK1490100T3 true DK1490100T3 (da) 2012-03-12

Family

ID=28676388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03720397.3T DK1490100T3 (da) 2002-03-28 2003-03-28 Kombinerede DNA/proteinvaccinepræparater

Country Status (9)

Country Link
US (1) US20050129712A1 (da)
EP (1) EP1490100B1 (da)
AT (1) ATE538808T1 (da)
AU (1) AU2003224017A1 (da)
CA (1) CA2480690A1 (da)
DK (1) DK1490100T3 (da)
ES (1) ES2379346T3 (da)
IL (1) IL164256A0 (da)
WO (1) WO2003082327A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA032364B1 (ru) 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
CN111388662B (zh) * 2020-03-12 2023-03-10 潍坊华英生物科技有限公司 一种小鹅瘟病毒的复合疫苗及卵黄抗体制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48365A1 (en) * 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
EP0880360B1 (en) * 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
WO2000002591A1 (en) * 1998-07-09 2000-01-20 Merck & Co., Inc. Polynucleotide vaccine formulations
GB9910375D0 (en) * 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition

Also Published As

Publication number Publication date
EP1490100A2 (en) 2004-12-29
WO2003082327A2 (en) 2003-10-09
US20050129712A1 (en) 2005-06-16
ES2379346T3 (es) 2012-04-25
AU2003224017A1 (en) 2003-10-13
EP1490100B1 (en) 2011-12-28
ATE538808T1 (de) 2012-01-15
WO2003082327A3 (en) 2004-03-04
CA2480690A1 (en) 2003-10-09
IL164256A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US20230210965A1 (en) PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
PT1117421E (pt) Novos metodos para vacinacao terapeutica
BR0311995A (pt) Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2009074861A3 (en) Improved vaccine
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
Buaklin et al. Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein
AU2667600A (en) Identification of specific differentially expressed antigens
DK1227840T3 (da) Adjuverede, genetiske vacciner
DK1913957T3 (da) Genetiske adjuvant-vacciner